


PE anti-human IL-13

Catalog # / Size: 3109515 / 25 tests
Clone: JES10-5A2
Isotype: Rat IgG1, κ
Immunogen: COS-expressed, recombinant human IL-13
Reactivity: Human
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide, 0.2% (w/v) BSA (USA origin).
Concentration: Lot-specific



PMA+ionomycin-stimulated T lymphocytes intracellularly stained with JES10-5A2 PE and CD4 (RPA-T4) APC

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: **ELISA or ELISPOT Capture^{1,2}:** The purified JES10-5A2 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated Poly5020 antibody (Cat. No. 502001) as the detecting antibody. The LEAF™ purified antibody is suggested for ELISPOT capture.
Flow Cytometry^{3,7}: The fluorochrome-labeled JES10-5A2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-13 -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section.
Neutralization¹: The LEAF™ purified antibody (Endotoxin **Additional reported applications (for the relevant formats) include:** Western blotting, immunohistochemical staining^{4-6,8} of paraformaldehyde-fixed, saponin-treated frozen tissue sections, and immunocytochemistry.

Application References:

- McKenzie, A., *et al.* 1994. *Curr. Prot. Immunol.*. John Wiley & Sons. New York. Section 6.18.
- Abrams, J. 1995. *Curr. Prot. Immunol.*. John Wiley and Sons, New York. Unit 6.20.
- Schaerli, P., *et al.* 2000. *J. Exp. Med.* 192:1553.
- Andersson, J., *et al.* 1994. *Immunology* 83:16.
- Skansen-Saphir, U., *et al.* 1994. *Eur. J. Immunol.* 24:916.
- Andersson, U., *et al.* 1999. *Detection and quantification of gene expression.* New York:Springer-Verlag.
- Gelfand, E. W., *et al.* 2006. *J. Aller. and Clinic. Immunol.* 117:577.
- Knorr, C., *et al.* 1999. *Am. J. Pathol.* 155:2019.
- Kongsbak M, *et al.* 2014. *PLoS One.* 9:96695. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25111111/)

Description: IL-13 is an immunoregulatory cytokine produced primarily by activated Th2 lymphocytes. IL-13 shares 30% amino acid sequence homology with IL-4 and demonstrates similar biological activities. The biological activities of IL-13 include: suppression of macrophage cytotoxic activity, upregulation of IL-1RA expression, and suppression of proinflammatory cytokine secretion. The JES10-5A2 antibody reacts with human interleukin-13 (IL-13). The JES10-5A2 antibody can neutralize the bioactivity of natural or recombinant IL-13.

Antigen
References: 1. Fitzgerald, K., *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.

2. Hilton, D., *et al.* 1996. *P. Natl. Acad. Sci. USA* 93:497.

3. Obiri, N., *et al.* 1995. *J. Biol. Chem.* 270:8